Due to its pivotal role as a "prime regulator" in inflammatory pathways, NFκB has been proposed as a therapeutic target for cancer by inhibiting NFκB to prevent the proliferation of cancer cells [14, 15]. The gene discussed is NFKB1; the disease is cancer.